Trump’s Proposed 200-250% Tariff on Pharma Imports to Lead to Drug Shortages and Higher Prices, Says GlobalData - GlobalData

Potential 250% Pharma Tariffs Could Pressure Margins Without Directly Raising Patient Costs

In the first part of his Pharma Commerce video interview, Dave Malenfant, a healthcare supply chain expert, explains how steep pharmaceutical import tariffs might affect costs at different points in the supply chain, why component pricing poses a bigger risk than active ingredients, and how insurers, distributors, and manufacturers may negotiate to shield patients from price increases.

Trump’s proposed 200-250% tariff on pharma imports to lead to drug shortages and higher prices, says GlobalData - GlobalData

The pharmaceutical industry is on high alert as US President Donald Trump proposes a 200-250% tariff on drug imports, which could significantly increase prices and reduce profit margins. While the tariffs are set to be announced soon, a grace period of 12 to 18 months has been indicated before they take effect. Even with this delay, production costs are likely to rise, potentially leading to drug shortages and higher consumer prices, says Global…